Stock 4RY AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Akeso, Inc. Börse Stuttgart

Equities

4RY

KYG0146B1032

Market Closed - Börse Stuttgart
Other stock markets
 11:34:51 05/07/2024 am IST 		5-day change 1st Jan Change
4.48 EUR +5.66% Intraday chart for Akeso, Inc. +2.28% -14.67%
01/07 Akeso, Inc. Announces Change of Directors CI
04/06 Akeso Expands Territory of License Agreement for Lung Cancer Drug MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Akeso, Inc. Announces Change of Directors
Akeso Expands Territory of License Agreement for Lung Cancer Drug
Summit Therapeutics Inc. Expands License Territories for Ivonescimab
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer
Akeso to Raise Over HK$1 Billion Via Share Sale
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC
Akeso Books First-Ever Profit in 2023; Shares Fall 5%
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. 4RY Stock
  5. News Akeso, Inc.
  6. Other languages